Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
181 hedge funds and large institutions have $2.29B invested in Apellis Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 79 increasing their positions, 53 reducing their positions, and 53 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 53
0% more call options, than puts
Call options by funds: $147M | Put options by funds: $147M
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0.36% less ownership
Funds ownership: 80.27% → 79.91% (-0.36%)
12% less funds holding
Funds holding: 205 → 181 (-24)
42% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 53
44% less capital invested
Capital invested by funds: $4.08B → $2.29B (-$1.79B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$224M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$84.6M |
| 3 |
JP Morgan Chase
New York
|
+$62.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$61.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$49.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$185M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$144M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$98M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$30.5M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$26M |
APLS Hedge Fund Activity: Q3 2021 in Review
181 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q3 2021, worth a combined $2.29B — down 44% from $4.08B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of APLS and 31 opened new positions — a net loss of 22 holders — while 53 trimmed existing stakes and 79 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $224M. The largest seller was HHLR Advisors, exiting entirely with an estimated $185M sold.
- 181 institutional investors held Apellis Pharmaceuticals (APLS) as of Q3 2021, down from 205 in Q2 2021.
- Funds reported $2.29B of Apellis Pharmaceuticals stock for Q3 2021, down 44% quarter-over-quarter.
- 31 funds opened new Apellis Pharmaceuticals positions in Q3 2021 and 53 closed out, a net change of -22 holders.
- The largest Apellis Pharmaceuticals buyer in Q3 2021 was Avoro Capital Advisors, an estimated $224M added.
- The largest Apellis Pharmaceuticals seller in Q3 2021 was HHLR Advisors, an estimated $185M sold.
Based on aggregated 13F filings for Q3 2021.